Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 5/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13396469 | 0.87 | MEN1 (0.41) | CA2MEN1KMT2ANOS1CYP2C9 | |
| SCHEMBL13396485 | 0.86 | MEN1 (0.41) | CA2MEN1KMT2ANOS1CYP2C9 | |
| SCHEMBL13396361 | 0.84 | DPP7 (0.41) | CA2NOS1TLR2 | |
| SCHEMBL13396402 | 0.82 | GNAI3 (0.49) | CA2MEN1KMT2ANOS1TLR2 | |
| SCHEMBL13396362 | 0.82 | RRM1 (0.40) | CA2NOS1TLR2 | |
| SCHEMBL13396409 | 0.81 | MEN1 (0.40) | CA2MEN1KMT2ANOS1TLR2 | |
| SCHEMBL13396522 | 0.80 | MEN1 (0.51) | CA2MEN1KMT2ACYP2C9ALOX15 | |
| SCHEMBL13396385 | 0.79 | NOS1 (0.41) | CA2MEN1KMT2ANOS1TLR2 | |
| SCHEMBL13396355 | 0.78 | PTGS2 (0.36) | CA2PTGS2 | |
| SCHEMBL13397199 | 0.78 | GLP1R (0.39) | CA2MEN1KMT2ANOS1TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | CA2 2652/4885MEN1 615/4885KMT2A 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.